Characterization of the Interaction of Ingenol 3-Angelate with Protein Kinase C

Cancer Research

Volumn 64, Issue 9, 2004, Pages 3243-3255

  Kedei, Noemi ^a   Lundberg, Daniel J ^a   Toth, Attila ^a   Welburn, Peter ^b   Garfield, Susan H ^a   Blumberg, Peter M ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b Peplin Ltd   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; DIACYLGLYCEROL; GREEN FLUORESCENT PROTEIN; INGENOL; INGENOL 3 ANGELATE; INTERLEUKIN 6; ISOPROTEIN; LIGAND; LIPID; PHORBOL 12 ACETATE 13 MYRISTATE; PHOSPHATIDYLSERINE; PROTEIN KINASE C; PROTEIN KINASE C DELTA; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BINDING AFFINITY; CANCER CELL CULTURE; CELL PROLIFERATION; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CYTOKINE RELEASE; DOSE RESPONSE; DRUG DISTRIBUTION; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SELECTIVITY; ENZYME ACTIVITY; EUPHORBIA; EUPHORBIA PEPLUS; HUMAN; HUMAN CELL; INFLAMMATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN LIPID INTERACTION; SENSITIVITY AND SPECIFICITY; SURFACE PLASMON RESONANCE; TRADITIONAL MEDICINE;

ANIMALS; CHO CELLS; CRICETINAE; DITERPENES; DOWN-REGULATION; EUPHORBIA; HUMANS; INTERLEUKIN-6; ISOENZYMES; LIGANDS; LIPOSOMES; PROTEIN KINASE C; TETRADECANOYLPHORBOL ACETATE;

EID: 2342613651     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-03-3403     Document Type: Article

References (78)

1. Mellor H, Parker PJ. The extended protein kinase C superfamily. Biochem J 1998; 332:281-92.
2. Dempsey EC, Newton AC, Mochly-Rosen D, et al. Protein kinase C isozymes and the regulation of diverse cell responses. Am J Physiol Lung Cell Mol Physiol 2000;279: L429-38.
3. Murray NR, Davidson LA, Chapkin RS, Clay Gustafson W, Schattenberg DG, Fields AP. Overexpression of protein kinase CβII induces colonic hyperproliferation and increased sensitivity to colon carcinogenesis. J Cell Biol 1999;145:699-711.
4. Reddig PJ, Dreckschmidt NE, Zou J, Bourguignon SE, Oberley TD, Verma AK. Transgenic mice overexpressing protein kinase Cε in their epidermis exhibit reduced papilloma burden but enhanced carcinoma formation after tumor promotion. Cancer Res 2000;60:595-602.
5. Reddig PJ, Dreckschmidt NE, Ahrens H, et al. Transgenic mice overexpressing protein kinase Cδ in the epidermis are resistant to skin tumor promotion by 12-O-tetradecanoylphorbol-13-acetate. Cancer Res 1999;59:5710-8.
6. Mischak H, Pierce JH, Goodnight J, Kazanietz MG, Blumberg PM, Mushinski JF. Phorbol ester-induced myeloid differentiation is mediated by protein kinase C-α and -δ and not by protein kinase C-βII, -ε, -ζ, and -η. J Biol Chem 1993;268:20110-5.
7. Deacon EM, Pongracz J, Griffiths G, Lord JM. Isoenzymes of protein kinase C: differential involvement in apoptosis and pathogenesis. Mol Pathol 1997;50:124-31.
8. Yuspa SH. The pathogenesis of squamous cell cancer: lessons learned from studies of skin carcinogenesis. J Dermatol Sci 1998;17:1-7.
9. Kuroki T, Kashiwagi M, Ishino K, Huh N, Ohba M. Adenovirus-mediated gene transfer to keratinocytes-a review. J Investig Dermatol Symp Proc 1999;4:153-7.
10. Rasmussen HH, Celis JE. Evidence for altered protein kinase C (PKC) signaling pathway in psoriasis. J Investig Dermatol 1993;101:560-6.
11. Aiello LP. The potential role of PKCβ in diabetic retinopathy and macular edema. Surv Ophthalmol 2002;47 Suppl 2:S263-9.
12. O'Brian CA, Ward NE, Stewart JR, Chu F. Prospects for targeting protein kinase C isozymes in the therapy of drug-resistant cancer-an evolving story. Cancer Metastasis Rev 2001;20:95-100.
13. Clamp A, Jayson GC. The clinical development of the bryostatins. Anticancer Drugs 2002;13:673-83.
14. Bocklandt S, Blumberg PM, Hamer DH. Activation of latent HIV-1 expression by the potent anti-tumor promoter 12-deoxyphorbol 13-phenylacetate. Antiviral Res 2003; 59:89-98.
15. Han ZT, Zhu XX, Yang RY, et al. Effect of intravenous infusions of 12-O-tetradecanoylphorbol-13-acetate (TPA) in patients with myelocytic leukemia: preliminary studies on therapeutic efficacy and toxicity. Proc Natl Acad Sci USA 1998;95: 5357-61.
16. Newton AC. Protein kinase C: structural and spatial regulation by phosphorylation, cofactors, and macromolecular interactions. Chem Rev 2001;101:2353-64.
17. Moscat J, Diaz-Meco MT. The atypical protein kinase Cs. Functional specificity mediated by specific protein adapters. EMBO Rep 2000;1:399-403.
18. Kazanietz MG. Novel "nonkinase" phorbol ester receptors: the C1 domain connection. Mol Pharmacol 2002;61:759-67.
19. Bittova L, Stahelin RV, Cho W. Roles of ionic residues of the C1 domain in protein kinase Cα activation and the origin of phosphatidylserine specificity. J Biol Chem 2001;276:4218-26.
20. Irie K, Nakahara A, Nakagawa Y, et al. Establishment of a binding assay for protein kinase C isozymes using synthetic C1 peptides and development of new medicinal leads with protein kinase C isozyme and C1 domain selectivity. Pharmacol Ther 2002;93:271-81.
21. Slater SJ, Ho C, Stubbs CD. The use of fluorescent phorbol esters in studies of protein kinase C-membrane interactions. Chem Phys Lipids 2002;116:75-91.
22. Giorgione J, Hysell M, Harvey DF, Newton AC. Contribution of the C1A and C1B domains to the membrane interaction of protein kinase C. Biochemistry 2003;42: 11194-202.
23. Hergenhahn M, Furstenberger G, Opferkuch HJ, Adolf W, Mack H, Hecker E. Biological assays for irritant tumor-initiating and -promoting activities. I. Kinetics of the irritant response in relation to the initiation-promoting activity of polyfunctional diterpenes representing tigliane and some daphnane types J Cancer Res Clin Oncol 1982;104:31-9.
24. Kraft AS, Smith JB, Berkow RL. Bryostatin, an activator of the calcium phospholipid-dependent protein kinase, blocks phorbol ester-induced differentiation of human promyelocytic leukemia cells HL-60. Proc Natl Acad Sci USA 1986;83:1334-8.
25. Hennings H, Blumberg PM, Pettit GR, Herald CL, Shores R, Yuspa SH. Bryostatin 1, an activator of protein kinase C, inhibits tumor promotion by phorbol esters in SENCAR mouse skin. Carcinogenesis (Lond) 1987;8:1343-6.
26. Dell'Aquila ML, Nguyen HT, Herald CL, Pettit GR, Blumberg PM. Bryostatin 1 inhibits the phorbol ester-induced blockage of differentiation in hexamethylene bisacetamide-treated Friend erythroleukemia cells. Cancer Res 1987;47:6006-9.
27. Szallasi Z, Krsmanovic L, Blumberg PM. Non-promoting 12-deoxyphorbol 13-esters inhibit phorbol 12-myristate 13-acetate induced tumor promotion in CD-1 mouse skin. Cancer Res 1993;53:2507-12.
28. Furstenberger G, Berry DL, Bertsch S, Sorg B, Marks F. Skin tumor promotion by phorbol esters is a two-stage process. Proc Natl Acad Sci USA 1981;78:7722-6.
29. Wada R, Suto Y, Kanal M, Shibasaki M. Dramatic switching of protein kinase C agonist/antagonist activity by modifying the 12-ester side chain of phorbol esters. J Am Chem Soc 2002;124:10658-9.
30. Zhang G, Kazanietz MG, Blumberg PM, Hurley JH. Crystal structure of the cys2 activator-binding domain of protein kinase Cδ in complex with phorbol ester. Cell 1995;81:917-24.
31. Hommel U, Zurini M, Luyten M. Solution structure of a cysteine rich domain of rat protein kinase C. Nat Struct Biol 1994;1:383-7.
32. Pak Y, Enyedy IJ, Varady J, et al. Structural basis of binding of high-affinity ligands to protein kinase C: prediction of the binding modes through a new molecular dynamics method and evaluation by site-directed mutagenesis. J Med Chem 2001; 44:1690-701.
33. 7.8-isoingenol. Z Naturforsch 1982;37b:748-56.
34. Green AC, Beardmore GL. Home treatment of skin cancer and solar keratoses. Australian J Dermatol 1988;29:127-30.
35. Weedon D, Chick J. Home treatment of basal cell carcinoma. Med J of Australia 1976;1:928.
36. Rizk AM, Hammouda FM, El-Missiry MM, Radwan HM, Evans FJ. Biologically active diterpene esters from Euphorbia peplus. Phytochemistry 1985;24:1605-6.
37. Adolf W, Chanai S, Hecker E. 3-O-angeloylingenol, the toxic and skin irritant factor from latex of Euphorbia antiquorum L. (Euphorbiaceae) and from a derived Thai purgative and anthelimintic (vermifuge) drug. J Sci Soc Thailand 1983;9:81-8.
38. Maynard K, Parsons PG. Cross sensitivity to methylating agents, hydroxyurea, and methotrexate in human tumor cells of the Mer phenotype. Cancer Res 1986;46: 5009-13.
39. Kazanietz MG, Areces LB, Bahador A, et al. Characterization of ligand and substrate specificity for the calcium-dependent and calcium-independent PKC isozymes. Mol Pharmacol 1993;44:298-307.
40. Kazanietz MG, Barchi JJ, Jr. Omichinski JG, Blumberg PM. Low affinity binding of phorbol esters to protein kinase C and its recombinant cysteine-rich region in the absence of phospholipids. J Biol Chem 1995;270:679-84.
41. 3H]Phorbol 12,13-dibutyrate binding assay for protein kinase C and related proteins. In: Alexandra C, ed. Protein kinase C protocols, Vol 233. Totowa, NJ: Newton, Humana Press; 2002. p. 129-56.
42. Nacro K, Bienfait B, Lee J, et al. Conformationally constrained analogues of diacylglycerol (DAG). 16. How much structural complexity is necessary for recognition and high binding affinity to protein kinase C? J Med Chem 2000;43:921-44.
43. Lorenzo PS, Bogi K, Acs P, Pettit GR, Blumberg PM. The catalytic domain of PKCδ confers protection from down regulation induced by bryostatin 1. J Biol Chem 1997;272:33338-43.
44. Wang QJ, Fang TW, Fenick D, et al. The lipophilicity of phorbol esters as a critical factor in determining the pattern of translocation of protein kinase C δ fused to a green fluorescent protein. J Biol Chem 2000;275:12136-46.
45. Szallasi Z, Denning MF, Smith CB, et al. Bryostatin 1 protects PKCδ from down-regulation in mouse keratinocytes in parallel with its inhibition of phorbol ester induced differentiation. Mol Pharmacol 1994;46:840-50.
46. Lint JV, Rykx A, Vantus T, Vandenheede JR. Getting to know protein kinase D. Int J Biochem Cell Biol 2002;34:577-81.
47. Norris JG, Tang LP, Sparacio SM, Benveniste EN. Signal transduction pathways mediating astrocyte IL-6 induction by IL-1β and tumor necrosis factor-α. J Immunol 1994;152:841-50.
48. Wang HQ, Smart RC. Overexpression of protein kinase C-α in the epidermis of transgenic mice results in striking alterations in phorbol ester-induced inflammation and COX-2, MIP-2 and TNF-α expression but not tumor promotion. J Cell Sci 1999;112:3497-506.
49. Hobbs MV, McEvilly RJ, Koch RJ, Cardenas GJ, Noonan DJ. Interleukin-6 production by murine B cells and B cell lines. Cell Immunol 1991;132:442-50.
50. Irie A, Chen YZ, Tsukamoto H, Jotsuka T, Masuda M, Nishimura Y. Unique T cell proliferation associated with PKCμ activation and impaired ZAP-70 phosphorylation in recognition of overexpressed HLA/partially agonistic peptide complexes. Eur J Immunol 2003;33:1497-507.
51. Bertolini TM, Giorgione J, Harvey DF, Newton AC. Protein kinase C translocation by modified phorbol esters with functionalized lipophilic regions. J Org Chem 2003;68: 5028-36.
52. Sando J, Chertihin OI, Owens JM, Kretsinger RH. Contribution to maxima in protein kinase C activation. J Biol Chem 1998;273:34022-7.
53. Goldberg EM, Zidovetzki R. Synergistic effects of diacylglycerols and fatty acids on membrane structure and protein kinase C activity. Biochemistry 1998;37:5623-32.
54. Garcia-Bermejo ML, Leskow FC, Fujii T, et al. Diacylglycerol (DAG)-lactones, a new class of protein kinase C-(PKC) agonists, induce apoptosis in LnCap prostate cancer cells by selective activation of PKCα J Biol Chem 2002;277:645-55.
55. Eto A, Akita Y, Saido TC, Suzuki K, Kawashima S. The role of the calpain-calpastatin system in thyrotropin-releasing hormone-induced selective down-regulation of a protein kinase C isozyme, nPKCε, in rat pituitary GH4C1 cells. J Biol Chem 1995;270:25115-20.
56. Lee HW, Smith L, Pettit GR, Smith JB. Bryostatin 1 and phorbol ester down-modulate protein kinase C-α and -ε via the ubiquitin/proteasome pathway in human fibroblasts. Mol Pharmacol 1997;51:439-47.
57. Junoy B, Maccario H, Mas JL, Enjalbert A, Drouva SV. Proteasome implication in phorbol ester- and GnRH-induced selective down-regulation of PKC (α, ε, ζ) in αT(3)-1 and LβT(2) gonadotrope cell lines. Endocrinology 2002;143:1386-403.
58. Sakai N, Sasaki K, Ikegaki N, Shirai Y, Ono Y, Saito N. Direct visualization of the translocation of the γ-subspecies of protein kinase C in living cells using fusion proteins with green fluorescent protein. J Cell Biol 1997;139:1465-76.
59. Oancea E, Meyer T. Protein kinase C as a molecular machine for decoding calcium and diacylglycerol signals. Cell 1998;95:307-18.
60. Nakashima S. Protein kinase Cα (PKCα): regulation and biological function. J Biochem (Tokyo) 2002;132:669-75.
61. Li L, Lorenzo PS, Bogi K, Blumberg PM, Yuspa SH. PKCδ targets mitochondria, alters mitochondrial membrane potential and induces apoptosis in normal and neoplastic keratinocytes when overexpressed by an adenoviral vector. Mol Cell Biol 1999;19:8547-58.
62. Wang QJ, Bhattacharyya DK, Garfield S, Marquez VE, Blumberg PM. Differential localization of protein kinase Cδ by phorbol esters and related compounds using a fusion protein with green fluorescent protein. J Biol Chem 1999;274:37233-9.
63. Akita Y. Protein Kinase C-ε (PKC-ε): its unique structure and function. J Biochem. (Tokyo) 2002;132:847-52.
64. Mochly-Rosen D, Gordon AS. Anchoring proteins for protein kinase C: a means for isozyme selectivity. FASEB J 1998;12:35-42.
65. Naka T, Nishimoto N, Kishimoto T. The paradigm of IL-6: from basic science to medicine. Arthritis Res 2002;4 Suppl 3:S233-42.
66. Akira S, Yoshida K, Tanaka T, Taga T, Kishimoto T. Targeted disruption of the IL-6 related genes: gp130 and NF-IL-6. Immunol Rev 1995;148:221-53.
67. Tanabe O, Akira S, Kamiya T, Wong GG, Hirano T, Kishimoto T. Genomic structure of the murine IL-6 gene. High degree conservation of potential regulatory sequences between mouse and human. J Immunol 1988;141:3875-81.
68. Sehgal PB. Regulation of IL6 gene expression. Res Immunol 1992;143:724-34.
69. Dendorfer U, Oettgen P, Libermann TA. Multiple regulatory elements in the interleukin-6 gene mediate induction by prostaglandins, cyclic AMP, and lipopolysaccharide. Mol Cell Biol 1994;14:4443-54.
70. Grimaldi M, Arcone R, Ciliberto G, Schettini G. Synergistic stimulation of interleukin 6 release and gene expression by phorbol esters and interleukin Iβ in rat cortical astrocytes: role of protein kinase C activation and blockade. J Neurochem 1995;64: 1945-53.
71. Carlson RO, Aschmies SH. Tyrosine kinase activity is essential for interleukin-1β-stimulated production of interleukin-6 in U373 human astrocytoma cells. J Neurochem 1995;65:2491-9.
72. Akashi M, Loussararian AH, Adelman DC, Saito M, Koeffler HP. Role of lymphotoxin in expression of interleukin 6 in human fibroblasts. Stimulation and regulation. J Clin Investig 1990;85:121-9.
73. Chano F, Descoteaux A. Modulation of lipopolysaccharide-induced NF-IL6 activation by protein kinase C-α in a mouse macrophage cell line. Eur J Immunol 2002;32:2897-904.
74. Bordin L, Priante G, Musacchio E, et al. Arachidonic acid-induced IL-6 expression is mediated by PKCα activation in osteoblastic cells. Biochemistry 2003;42:4485-91.
75. Radeff JM, Nagy Z, Stern PH. Involvement of PKC-β in PTH, TNF-α, and IL-1β effects on IL-6 promoter in osteoblastic cells and on PTH-stimulated bone resorption. Exp Cell Res 2001;268:179-88.
76. Miyamoto A, Nakayama K, Imaki H, et al. Increased proliferation of B cells and auto-immunity in mice lacking protein kinase Cδ. Nature (Lond) 2002;416:865-9.
77. Dornand J, Bouaboula M, d'Angeac AD, Favero J, Shire D, Casellas P. Contrasting effects of the protein kinase C inhibitor staurosporine on the interleukin-1 and phorbol ester activation pathways in the EL4-6.1 thymoma cell line J Cell Physiol 1992; 151:71-80.
78. Marquez VE, Blumberg PM. Diacylglycerol (DAG) and DAG-lactones as selective activators of protein kinase C (PK-C). Acc Chem Res 2003;36:434-43.